Edwards Lifesciences has announced strategic acquisitions of JenaValve Technology and Endotronix to expand its structural heart portfolio.
These investments aim to address unmet patient needs and drive long-term growth within the structural heart sector.
The upfront purchase price for these investments totals nearly $1.2bn, with the finalisation of the deals contingent on regulatory approvals.
JenaValve Technology provides transcatheter treatment of aortic regurgitation (AR). The company’s Trilogy Heart Valve System is expected to receive approval from the US Food and Drug Administration in late 2025 to treat AR.
Edwards has also exercised its option to acquire Endotronix, enhancing its capabilities in the heart failure (HF) management space.
This acquisition is expected to expand Edwards's structural heart portfolio into a new therapeutic area for addressing the needs of HF patients.
Edwards CEO Bernard Zovighian said: “These acquisitions expand our opportunities to address the unmet needs of aortic regurgitation and heart failure patients around the world.
“We are pleased to enter these structural heart therapeutic areas with innovation, world-class science and clinical evidence to provide access to life-saving technologies for patients around the world.”
These strategic moves are anticipated to boost Edwards' position as a leader in structural heart innovation.
Furthermore, the company expects minimal revenue contribution from the acquisitions of JenaValve and Endotronix in 2025.
Last week, Edwards said it was exercising its option to acquire Israeli company Innovalve Bio Medical to advance its early-stage transcatheter mitral valve replacement (TMVR) business.
In an official filing with the US Securities and Exchange Commission, Edwards said it expects to pay around $300m in cash at the closing of the acquisition.
